{"entity":{"id":"nct05288205","kind":"trial","name":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","aka":[],"tldr":"A phase 1/2 trial of Glecirasib, Sitneprotafib in non-small-cell lung cancer and small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.","summary":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation is a phase 1/2 interventional study registered as NCT05288205 by Allist Pharmaceuticals, Inc., with 240 participants planned, started 2022-04-14 and due to reach its primary completion in 2027-03. Interventions recorded: JAB-21822, JAB-3312. Conditions listed: KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05288205","url":"https://clinicaltrials.gov/study/NCT05288205"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","colorectal","kras-g12c-colorectal","kras-g12c-nsclc"],"sections":[],"technologies":["kinase-inhibitors","kras-inhibitors"],"targets":[],"drugs":["glecirasib","sitneprotafib"],"companies":["allist"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05288205-lancet-respir-med-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05288205","phase":"1/2","setting":"A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","sponsor":"Allist Pharmaceuticals, Inc.","started":"2022-04-14","startedType":"actual","enrolled":240,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05288205/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/"},{"id":"sitneprotafib","kind":"drug","name":"Sitneprotafib","route":"/drugs/sitneprotafib/"}],"company":[{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}],"paper":[{"id":"paper-nct05288205-lancet-respir-med-2026","kind":"paper","name":"Glecirasib plus sitneprotafib in patients with KRAS G12C -mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial","route":"/key-papers/paper-nct05288205-lancet-respir-med-2026/"}]}}